MétaCan
Menu
Back to cohort
Record W4391268341 · doi:10.1016/j.jacadv.2023.100780

Heparin Dose Intensity and Organ Support-Free Days in Patients Hospitalized for COVID-19

2024· article· en· W4391268341 on OpenAlexafffund
Lucas C. Godoy, Matthew D. Neal, Ewan C. Goligher, Mary Cushman, Brett L. Houston, Charlotte Bradbury, Zoe McQuilten, Tobias Tritschler, Susan R. Kahn, Lindsay R. Berry, Elizabeth Lorenzi, Alisa M. Higgins, Lucy Z. Kornblith, Jeffrey S. Berger, Michelle N. Gong, Jonathan Paul, Lana A. Castellucci, Grégoire Le Gal, Sylvain Lother, Robert S. Rosenson, Lennie Derde, Anand Kumar, Bryan J. McVerry, José Carlos Nicolau, Eric Leifer, Jorge Escobedo, David T. Huang, Harmony R. Reynolds, Marc Carrier, Keri S. Kim, Beverley J. Hunt, Arthur S. Slutsky, Alexis F. Turgeon, Steven Webb, Colin McArthur, Michael E. Farkouh, Judith S. Hochman, Ryan Zarychanski, Patrick R. Lawler

Bibliographic record

VenueJACC Advances · 2024
Typearticle
Languageen
FieldMedicine
TopicCOVID-19 Clinical Research Studies
Canadian institutionsUniversité LavalSt. Michael's HospitalInstitut du Savoir MontfortUniversity of OttawaMcGill University Health CentreCentre hospitalier universitaire de QuébecOttawa HospitalUniversity of ManitobaCancerCare ManitobaUniversity of TorontoUniversity Health Network
FundersCanadian Institutes of Health ResearchNational Institutes of Health
KeywordsMedicineHeparinTherapeutic indexRandomized controlled trialRandomizationConfidence intervalClinical trialInternal medicineAnesthesiaPharmacologyDrug

Abstract

fetched live from OpenAlex

Background: Clinical trials suggest that therapeutic-dose heparin may prevent critical illness and vascular complications due to COVID-19, but knowledge gaps exist regarding the efficacy of therapeutic heparin including its comparative effect relative to intermediate-dose anticoagulation. Objectives: The authors performed 2 complementary secondary analyses of a completed randomized clinical trial: 1) a prespecified per-protocol analysis; and 2) an exploratory dose-based analysis to compare the effect of therapeutic-dose heparin with low- and intermediate-dose heparin. Methods: Patients who received initial anticoagulation dosed consistently with randomization were included. The primary outcome was organ support-free days (OSFDs), a combination of in-hospital death and days free of organ support through day 21. Results: Among 2,860 participants, 1,761 (92.8%) noncritically ill and 857 (89.1%) critically ill patients were treated per-protocol. Among noncritically ill per-protocol patients, the posterior probability that therapeutic-dose heparin improved OSFDs as compared with usual care was 99.3% (median adjusted OR: 1.36; 95% credible interval [CrI]: 1.07-1.74). Therapeutic heparin had a high posterior probability of efficacy relative to both low- (94.6%; adjusted OR: 1.26; 95% CrI: 0.95-1.64) and intermediate- (99.8%; adjusted OR: 1.80; 95% CrI: 1.22-2.62) dose thromboprophylaxis. Among critically ill per-protocol patients, the posterior probability that therapeutic heparin improved outcomes was low. Conclusions: Among noncritically ill patients hospitalized for COVID-19 who were randomized to and initially received therapeutic-dose anticoagulation, heparin, compared with usual care, was associated with improved OSFDs, a combination of in-hospital death and days free of organ support. Therapeutic heparin appeared superior to both low- and intermediate-dose thromboprophylaxis.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.056
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.353
Threshold uncertainty score0.952

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.056
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.040
GPT teacher head0.434
Teacher spread0.394 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueJACC AdvancesSame topicCOVID-19 Clinical Research StudiesFrench-language works237,207